DRTG(SH:600329)2023-04-28 16:00Financial Performance - The company's operating revenue for Q1 2023 was RMB 2,154,405,776.85, representing a year-on-year increase of 14.03%[4] - Net profit attributable to shareholders was RMB 400,788,396.53, showing a significant increase of 100.79% compared to the same period last year[4] - Basic and diluted earnings per share both stood at RMB 0.52, marking a 100% increase year-on-year[4] - Total operating revenue for Q1 2023 reached ¥2,154,405,776.85, an increase of 14.05% compared to ¥1,889,294,355.26 in Q1 2022[16] - Net profit for Q1 2023 was ¥397,782,701.63, compared to ¥202,246,413.81 in Q1 2022, representing a growth of 96.59%[18] - Earnings per share for Q1 2023 were ¥0.52, doubling from ¥0.26 in Q1 2022[19] - The total comprehensive income for Q1 2023 was ¥397,884,789.40, compared to ¥201,906,275.33 in Q1 2022, reflecting an increase of 97.00%[18] Cash Flow - The net cash flow from operating activities reached RMB 186,966,594.00, reflecting a year-on-year growth of 137.21%[4] - Cash inflow from operating activities for Q1 2023 was approximately ¥2.21 billion, an increase of 24% compared to ¥1.78 billion in Q1 2022[20] - Net cash flow from operating activities reached ¥186.97 million in Q1 2023, up from ¥78.82 million in Q1 2022, representing a growth of 137%[20] - Total cash inflow from investment activities was ¥116.36 million in Q1 2023, a decrease of 73% from ¥435.31 million in Q1 2022[21] - Net cash flow from financing activities was ¥323.50 million in Q1 2023, compared to a net outflow of ¥17.52 million in Q1 2022[21] - The net increase in cash and cash equivalents for Q1 2023 was approximately ¥582.34 million, compared to an increase of ¥411.10 million in Q1 2022[21] Assets and Liabilities - Total assets at the end of the reporting period were RMB 10,866,527,859.66, up 6.99% from the end of the previous year[5] - The total liabilities have increased to RMB 3,560,725,598.61 from RMB 3,333,434,867.96, suggesting a rise in financial obligations[14] - The company's total liabilities increased to ¥3,933,820,819.32 in Q1 2023 from ¥3,605,028,900.58 in Q1 2022, marking a rise of 9.09%[17] - The total equity attributable to shareholders reached ¥6,905,220,131.40 in Q1 2023, up from ¥6,521,460,534.99 in Q1 2022, an increase of 5.88%[17] Expenses - Sales expenses rose by 39% primarily due to the increase in sales revenue[9] - Financial expenses increased by 64%, mainly attributed to higher interest costs[9] - Research and development expenses for Q1 2023 were ¥24,195,352.76, compared to ¥19,332,928.57 in Q1 2022, indicating a rise of 25.31%[17] - Cash paid to employees in Q1 2023 was ¥243.44 million, an increase of 22% from ¥199.52 million in Q1 2022[20] - Cash paid for taxes in Q1 2023 was ¥229.69 million, significantly higher than ¥98.40 million in Q1 2022, indicating a growth of 133%[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 26,433, with the largest shareholder, Tianjin Pharmaceutical Group Co., Ltd., holding 331,120,528 shares, accounting for 42.811% of the total[10] Other Income - The company reported a 655% increase in other income, mainly from government subsidies received[9] - The company reported a financial income of ¥12,287,594.48 in Q1 2023, down from ¥13,078,314.45 in Q1 2022[17] Current Assets - As of March 31, 2023, the company's total current assets amount to RMB 7,903,764,059.62, an increase from RMB 7,245,444,756.23 in the previous year[13] - The company's cash and cash equivalents stand at RMB 3,455,307,279.55, compared to RMB 2,882,523,954.61 as of December 31, 2022, reflecting a significant increase[13] - Accounts receivable have risen to RMB 2,440,287,659.57 from RMB 2,146,213,416.31 year-over-year, indicating a growth in sales or credit terms[13] Financial Management - The company reported a decrease in accounts payable, which fell to RMB 686,731,735.62 from RMB 724,326,434.25, indicating improved cash flow management[14] - The company has a significant increase in short-term borrowings, which rose to RMB 351,276,795.73 from RMB 101,638,515.28[14] Intangible Assets - The company has maintained a stable level of intangible assets, which increased to RMB 332,127,671.68 from RMB 281,127,790.71[14] Product Development - The company has not disclosed any significant new product developments or market expansion strategies in the current report[12]